LGD-4033, often referred to as LGD4033, is an investigational selective androgen receptor module, or SARM. Since it was only founded a few years ago, LGD-4033 falls under the Investigational New Drug category. Scientists are looking at a variety of potential use cases when it comes to LGD-4033 supplementation, not the least of which includes treatment for osteoporosis and muscle degeneration.
Since the FDA has accepted LGD-4033 as a part of the Investigational New Drug (IND) program, studies have really increased. The IND program allows a company approved by the FDA to start human clinical trials, as a result of promising research studies completed on test animals.
Cause for Concern – Nullified
SARMs like LGD-4033 are always met with a certain level of concern and apprehension. Most SARMs appear to affect testosterone levels and other hormone baselines. Adverse effects can lead to some long term damage in many cases of SARM supplementation. The preliminary research suggested that LGD-4033 was different. Testosterone levels do not seem to be affected, certainly from a long term standpoint.
In 2013, a team of learned scientists completed a 21 day study, monitoring the health and hormones of 76 test subjects involved. All of the men, 21 to 50 years of age, did not see any adverse side effects during the 21 day study! The men were monitored for 5 weeks after the conclusion of the LGD-4033 supplementation study. None of them saw late-blooming side effects either.
Current State of LGD-4033
Before production of large scale medications can begin, more studies need to be completed. In 2016, a study was completed focusing on the optimization and efficiency of SARMs, including LGD-4033. The results of the thorough research project showed that LGD-4033, despite the fact that it doesn’t share the same unwanted side effects as the other SARMs, can be stimulated and enhanced.
The majority of the research completed over the past two years has been in an effort to determine the best methods of LGD-4033 stimulation and optimization. If you’re looking to conduct your own experiments, you can get a standard 30ml bottle of LGD-4033 for a reasonable price. As with all of the products on our site, the LGD-4033 is intended for laboratory research use only.
Future of LGD-4033
Without a crystal ball, predicting the future of LGD-4033 is just speculation. That said, if the past few years are to be used as any sort of indicator, we can make some educated guesses. At some point, somebody is going to have a major breakthrough when it comes to utilizing LGD-4033 to treating muscle and skeleton diseases without running in to adverse side effects. It’s been five years since speculation really began. Developing a cost-effective way to treat osteoporosis and sarcopenia has since been treated as a top agenda item for big pharma companies. It’s not out of the realm of possibility that we’ll have successful treatments and medicines developed to help people cope with these horrible diseases. Once we have taken that large step, we’ll be able to look toward permanent eradication of the diseases through vaccination!
1. Shehzad Basaria, Lauren Collins, E. Lichar Dillon, Katie Orwoll, Thomas W. Storer, Renee Miciek, Jagadish Ulloor, Anqi Zhang, Richard Eder, Heather Zientek, Gilad Gordon, Syed Kazmi, Melinda Sheffield-Moore, Shalender Bhasin. “The Safety, Pharmacokinetics, and Effects of LGD-4033, a Novel Nonsteroidal Oral, Selective Androgen Receptor Modulator, in Healthy Young Men.” Journal Sci Med., U.S. National Library of Medicine, Jan 2013, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4111291/. 2. Anthony L. Handlon, Lee T. Schaller, Lisa M. Leesnitzer, Raymond V. Merrihew, Chuck Poole, John C. Ulrich, Joseph W. Wilson, Rodolfo Cadilla, Philip Turnbull. “Optimizing Ligand Efficiency of Selective Androgen Receptor Modulators (SARMs).” ACS Med Chem, U.S. National Library of Medicine, Jan 2016, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4716610/. 3. Christian M. Girgis, Nancy Mokbel, Douglas J. DiGirolamo. “Therapies for Musculoskeletal Disease: Can we Treat Two Birds with One Stone?.” Curr. Osteoporosis Rep, U.S. National Library of Medicine, Jun 2014, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4083371/.